DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark

DiscGenics announced that the first 30 subjects have been safely treated in its first-in-human U.S. clinical study of IDCT, an allogeneic injectable disc cell therapy for mild to moderate degenerative disc disease. An independent data safety monitoring committee reported no safety issues and recommended that the trial continues with no changes to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us